Liposomal Encapsulation of Citicoline for Ocular Drug Delivery
-
Published:2023-11-28
Issue:23
Volume:24
Page:16864
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Bonechi Claudia12ORCID, Mahdizadeh Fariba Fahmideh1ORCID, Talarico Luigi13ORCID, Pepi Simone13, Tamasi Gabriella12ORCID, Leone Gemma13ORCID, Consumi Marco13ORCID, Donati Alessandro12, Magnani Agnese13ORCID
Affiliation:
1. Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy 2. Centre for Colloid and Surface Science (CSGI), University of Florence, Via della Lastruccia 3, 50019 Sesto Fiorentino, Italy 3. National Interuniversity Consortium of Materials Science and Technology (INSTM), Via G. Giusti 9, 50121 Firenze, Italy
Abstract
Glaucoma represents a group of neurodegenerative diseases characterized by optic nerve damage and the slowly progressive death of retinal ganglion cells. Glaucoma is considered the second leading cause of irreversible blindness worldwide. Pharmaceutical treatment of glaucoma is critical because of the properties of the ocular barrier that limit the penetration of drugs, resulting in lower systemic bioavailability. This behavior causes the need of frequent drug administration, which leads to deposition of concentrated solutions on the eye, causing toxic effects and cellular damage to the eye. To overcome these drawbacks, novel drug-delivery systems, such as liposomes, can play an important role in improving the therapeutic efficacy of antiglaucomatous drugs. In this work, liposomes were synthesized to improve various aspects, such as ocular barrier penetration, bioavailability, sustained release of the drug, targeting of the tissue, and reduction in intraocular pressure. Citicoline (CDP-choline; cytidine 5′-diphosphocholine) is an important intermediate in the biosynthesis of cell membrane phospholipids, with neuroprotective and neuroenhancement properties, and it was used in the treatment on retinal function and neural conduction in the visual pathways of glaucoma patients. In this study, citicoline was loaded into the 1,2-dioleoyl-sn-glycerol-3-phosphocholine and cholesterol liposomal carrier to enhance its therapeutic effect. The citicoline encapsulation efficiency, drug release, and size analysis of the different liposome systems were investigated using dynamic light scattering, nuclear magnetic resonance, infrared spectroscopy, and ToF-SIMS experiments.
Funder
European Union cofinancing
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference34 articles.
1. Boia, R., Ruzafa, N., Aires, I.D., Pereiro, X., Ambrósio, A.F., Vecino, E., and Santiago, A.R. (2020). Neuroprotective strategies for retinal ganglion cell degeneration: Current status and challenges ahead. Int. J. Mol. Sci., 21. 2. Cytidine 51-diphosphocholine (citicoline) in glaucoma: Rationale of its use, current evidence and future perspectives;Roberti;Int. J. Mol Sci.,2015 3. Transneuronal degeneration in the brain during glaucoma;You;Front. Aging Neurosci.,2021 4. Gandolfi, S., Marchini, G., Caporossi, A., Scuderi, G., Tomasso, L., and Brunoro, A. (2020). Cytidine 50-diphosphocholine (citicoline): Evidence for a neuroprotective role in glaucoma. Nutrients, 12. 5. Citicoline and Retinal Ganglion Cells: Effects on Morphology and Function;Parisi;Curr. Neuropharmacol.,2018
|
|